Triple
T4850375
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Pfizer |
E108398
|
entity |
| Predicate | developed |
P73
|
FINISHED |
| Object | Pfizer–BioNTech COVID-19 vaccine |
E335285
|
NE FINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Pfizer–BioNTech COVID-19 vaccine | Statement: [Pfizer, developed, Pfizer–BioNTech COVID-19 vaccine]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Pfizer–BioNTech COVID-19 vaccine Context triple: [Pfizer, developed, Pfizer–BioNTech COVID-19 vaccine]
-
A.
Janssen COVID-19 Vaccine
The Janssen COVID-19 Vaccine is a single-dose, viral vector-based coronavirus vaccine developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, for the prevention of COVID-19.
-
B.
Pfizer–BioNTech
chosen
Pfizer–BioNTech is a pharmaceutical partnership best known for developing one of the first widely authorized mRNA vaccines against COVID-19.
-
C.
Moderna
Moderna is a biotechnology company best known for pioneering mRNA-based vaccines, including one of the first widely used COVID-19 vaccines.
-
D.
Sinovac
Sinovac is a Chinese biopharmaceutical company best known globally for developing the inactivated COVID-19 vaccine CoronaVac.
-
E.
COVID-19 vaccines
COVID-19 vaccines are immunizations developed to protect against the SARS-CoV-2 virus, significantly reducing the risk of severe illness, hospitalization, and death from COVID-19.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69bd440a89548190a5f14ba6da6b97dc |
completed | March 20, 2026, 12:56 p.m. |
| NER | Named-entity recognition | batch_69bd6d1e5cf08190bd6b6a524748f170 |
completed | March 20, 2026, 3:51 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69be67da14d48190a994a11eb7a674b5 |
completed | March 21, 2026, 9:41 a.m. |
Created at: March 20, 2026, 1:25 p.m.